RIVASTIGMINE
Clinical safety rating: caution
Animal studies have proved adverse effects but may be safe for humans
Reversible acetylcholinesterase inhibitor that enhances cholinergic function by increasing the concentration of acetylcholine at synaptic sites. Also inhibits butyrylcholinesterase.
| Metabolism | Primarily metabolized by cholinesterase-mediated hydrolysis, with minor involvement of CYP isozymes. |
| Excretion | Renal: ~97% total (mostly metabolites, <1% unchanged); fecal: negligible; biliary: minor. |
| Half-life | Terminal half-life ~1.5 h (oral, transdermal); clinical context: due to prolonged binding to acetylcholinesterase (AChE), effective half-life for AChE inhibition is ~10 h; steady state reached in 6-12 weeks. |
| Protein binding | ~40% bound to albumin; low protein binding, minimal displacement interactions. |
| Volume of Distribution | 1.8-2.7 L/kg; extensive extravascular distribution, penetrates CNS (CSF concentration ~40% of plasma). |
| Bioavailability | Oral: ~35-40% (low due to first-pass metabolism); transdermal: ~50-60% (relative to oral). |
| Onset of Action | Oral: 45-60 min (clinical effect); transdermal: 6-16 h (gradual onset, optimal steady state at 24 h). |
| Duration of Action | Oral: ~6-12 h (due to prolonged AChE inhibition despite short plasma half-life); transdermal: 24 h (once-daily application). |
1.5 mg orally twice daily initially, titrated by 1.5 mg/dose every 2 weeks to maintenance dose of 3-6 mg twice daily. Alternatively, transdermal patch: 4.6 mg/24h initially, titrate to 9.5 mg/24h after 4 weeks, then 13.3 mg/24h if tolerated.
| Dosage form | FILM, EXTENDED RELEASE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (GFR ≥30 mL/min). Caution in severe renal impairment (GFR <30 mL/min); use lowest effective dose and titrate slowly. |
| Liver impairment | Child-Pugh A and B: No adjustment; Child-Pugh C: Not recommended due to increased exposure. |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established. Off-label use in some conditions: start 0.5 mg/kg/day divided twice daily, titrate slowly to maximum 6 mg/kg/day, but no standard weight-based guidelines. |
| Geriatric use | Initiate at low end of dosing range; titrate slowly due to increased sensitivity and higher risk of adverse effects. No specific dose adjustment required but monitor closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Other cholinergic agents can have additive effects Can cause nausea vomiting and weight loss.
| Breastfeeding | No data available on rivastigmine excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions (e.g., cholinergic toxicity) in nursing infants, discontinue breastfeeding or discontinue drug, considering importance to mother. |
| Teratogenic Risk | FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; limited human data. First trimester: insufficient data to assess risk; second and third trimesters: no increased risk of major malformations reported. May cause fetal neuromuscular effects (muscle weakness) due to acetylcholinesterase inhibition, especially near term. |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | Parkinson's disease dementia |
| Serious Effects |
["Hypersensitivity to rivastigmine or any component of the formulation.","Known history of severe adverse reaction to any cholinesterase inhibitor."]
| Precautions | ["Gastrointestinal adverse reactions (nausea, vomiting, diarrhea, anorexia, weight loss) may occur, especially during titration.","Increased risk of gastrointestinal bleeding, particularly in patients with risk factors (e.g., NSAID use).","May exacerbate extrapyramidal symptoms in Parkinson's disease.","Risk of bradycardia and heart block, especially in patients with sick sinus syndrome or other conduction abnormalities.","May worsen urinary obstruction or seizures."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal vital signs (especially heart rate, blood pressure) for bradycardia or hypotension. Assess for signs of cholinergic excess (e.g., GI upset, salivation, lacrimation). Fetal monitoring: consider fetal heart rate monitoring if used near term due to possible fetal neuromuscular effects. No routine special monitoring required. |
| Fertility Effects | Animal studies showed no impairment of fertility at doses up to 19 times human exposure. In humans, no specific studies on fertility; potential for reversible cholinergic adverse effects (e.g., nausea, vomiting) that could indirectly affect reproductive function. No confirmed effects on spermatogenesis or ovulation. |